EGFR and neoplasm: First analysis of this clinical trial reported stable disease in 6/11 patients (55%) in the cohort of EGFR exon 20 insertions and tumor reduction by RECIST in 4/9 evaluable patients (44%) in the cohort of HER2 activating mutation.12